Stifel Financial Corp Royalty Pharma PLC Transaction History

Stifel Financial Corp

$93.2 Billion
Q3 2024

A detailed history of Stifel Financial Corp transactions in Royalty Pharma PLC stock. As of the latest transaction made, Stifel Financial Corp holds 19,352 shares of RPRX stock, worth $497,346. This represents 0.0% of its overall portfolio holdings.

Number of Shares

19,352

Previous 19,882 2.67%

Holding current value

$497,346

Previous $524,000 4.39%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$25.63 - $29.27 $13,583 - $15,513	-530 Reduced 2.67%	19,352 $547,000
Q2 2024 Aug 13, 2024	BUY	$26.26 - $29.9 $317,614 - $361,640	12,095 Added 155.32%	19,882 $524,000
Q1 2024 May 13, 2024	BUY	$27.46 - $31.33 $213,831 - $243,966	7,787 New	7,787 $236,000
Q2 2023 Aug 14, 2023	BUY	$29.6 - $36.56 $102,534 - $126,643	3,464 Added 55.62%	9,692 $297,000
Q1 2023 May 12, 2023	BUY	$32.77 - $39.4 $204,091 - $245,383	6,228 New	6,228 $224,000
Q3 2022 Nov 14, 2022	BUY	$39.88 - $44.65 $120,397 - $134,798	3,019 Added 5.67%	56,268 $2.26 Million
Q2 2022 Aug 15, 2022	BUY	$37.53 - $44.22 $1.68 Million - $1.98 Million	44,829 Added 532.41%	53,249 $2.24 Million
Q1 2022 May 13, 2022	SELL	$37.46 - $42.44 $135,642 - $153,675	-3,621 Reduced 30.07%	8,420 $329,000
Q4 2021 Feb 14, 2022	BUY	$35.17 - $42.48 $228,429 - $275,907	6,495 Added 117.11%	12,041 $480,000
Q3 2021 Nov 15, 2021	BUY	$36.14 - $42.24 $8,131 - $9,504	225 Added 4.23%	5,546 $201,000
Q2 2021 Aug 13, 2021	SELL	$39.85 - $46.63 $2,191 - $2,564	-55 Reduced 1.02%	5,321 $218,000
Q1 2021 May 14, 2021	BUY	$42.34 - $52.82 $227,619 - $283,960	5,376 New	5,376 $235,000

Others Institutions Holding RPRX

# of Institutions

412

Shares Held

283M

Call Options Held

578K

Put Options Held

47.5K

View Full List

About Royalty Pharma plc

Ticker RPRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 437,139,008
Market Cap $11.2B
Description
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic i...

More about RPRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Stifel Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Stifel Financial Corp with notifications on news.

Account

Stifel Financial Corp Royalty Pharma PLC Transaction History